Get started
Author

Deepali Varma

Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
2020 · Winfried M. Amoaku, Faruque Ghanchi, et al. · Eye · 231
PDF
Faricimab Treat-and-Extend for Diabetic Macular Edema
2023 · Tien Y. Wong, Zdenka Haskova, et al. · Ophthalmology · 195
PDF
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
2024 · David M Brown, David S Boyer, et al. · The Lancet · 159
PDF
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab
2023 · Raffaele Raimondi, Tina Felfeli, et al. · Ophthalmology Retina · 60
Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept
2019 · Justus G. Garweg, Jana Stefanickova, et al. · Ophthalmology Retina · 35
PDF
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
2019 · Richard P Gale, Ian Pearce, et al. · British Journal of Ophthalmology · 30
PDF
A Case Series on Chronic Canaliculitis
2005 · Deepali Varma, B. Y. P. Chang, et al. · Orbit · 30
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial
2023 · Masahiko Shimura, Shigehiko Kitano, et al. · Japanese Journal of Ophthalmology · 23
PDF
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
2022 · Justus G. Garweg, Jana Štefanickova, et al. · Advances in Therapy · 19
PDF
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study
2025 · Tunde Peto, Ian Pearce, et al. · Eye · 14
PDF
Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
2020 · Winfried M. Amoaku, Faruque Ghanchi, et al. · Eye · 14
PDF
A novel approach to expanding the role of nurses to deliver intravitreal injections for patients with age-related macular degeneration
2013 · Deepali Varma, David Lunt, et al. · International Journal of Ophthalmic Practice · 13
The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK
2024 · Rupert R. A. Bourne, Malik Moledina, et al. · Eye · 9
PDF
Intravitreal dexamethasone for central retinal vein occlusion with low visual acuity: a retrospective study
2013 · Christiana Dinah, Kapka Nenova, et al. · British Journal of Ophthalmology · 4
Improved Response To Ranibizumab In Ex And Current Smokers With Age-related Macular Degeneration (AMD), But No Evidence That CFH, ARMS2/HTRA1 Or VEGF Genotypes Predict Treatment Outcome
2012 · Chris F. Inglehearn, Manir Ali, et al. · Investigative Ophthalmology & Visual Science · 4
Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study
2026 · James Talks, Gabriella de Salvo, et al. · Eye · 3
PDF
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
2025 · Kiyoshi Suzuma, Toshinori Murata, et al. · Japanese Journal of Ophthalmology · 1
PDF
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort
2024 · Clare Bailey, Manju Chandran, et al. · Eye · 1
PDF
Inclusive research in ophthalmology is mission critical! The 10-point action plan
2023 · Christiana Dinah, Olayinka Williams, et al. · Eye · 1
PDF
Real life experience of combined fixed-dosing and Treat and Extend protocols for the treatment of Diabetic Macular Oedema (DMO) with Anti-Vascular Endothelial Growth Factors (VEGF) agents
2017 · Karim El-Assal, Alex Stubbing-Moore, et al. · Investigative Ophthalmology & Visual Science · 1
Real life clinical audit on Neo-vascular age related macular degeneration (nAMD) - comparing fixed dose Aflibercept versus PRN Ranibizumab (RBZ) over 12 months.
2015 · Romeela Rana-Rahman, Ajay Kotagiri, et al. · Investigative Ophthalmology & Visual Science · 1
Exploring the mixed marketing authorisation pathway: a case study in ophthalmology
2026 · Luke Nicholson, Deepali Varma · Eye
PDF
A commentary on the updated research priorities in ophthalmology: implications and future directions
2026 · Rupert R. A. Bourne, Malik Moledina, et al. · Eye
PDF
Real-life outcomes of dexamethasone intravitreal implant (Ozurdex) in diabetic macular oedema for treatment-naive eyes compared to anti-VEGF non-responders at three months post-treatment
2021 · Ali E. Ghareeb, Tiffany Lau, et al. · Investigative Ophthalmology & Visual Science
Functional and Structural Outcomes of Patients with Diabetic macular oedema treated with multiple Ozurdex implants at 24 months – Real Life Data
2021 · Tiffany Lau, Ali E. Ghareeb, et al. · Investigative Ophthalmology & Visual Science
Works count: 33
Citation count: 848
H-index: 12
I10-index: 12
Year
Topic
Type